PARP1 and multiple sclerosis: There are, however, contrasting reports in the literature showing that PARP-1 inhibition by 4-hydroxyquinazoline (4HQ) prevents oligodendrocyte death in diseases such as multiple sclerosis and ischemia [56,57].